[Myelodysplastic syndromes--pathogenesis and treatment].
The essence of myelodysplastic syndromes is damage of CFU. We can also observe different chromosomes' defects which in consequence cause disorder of differentiation and maturation of hematopoietic cells. The aim of therapy is elimination of damaged CFU, possible only by bone marrow transplant. Patients who can not qualify for a transplant are treated by pharmacologic means. Pharmacological treatment aims to induce differentiation of hematopoietic cells and also to inhibit apoptosis. Since in this disease multiple genetics anomalies are affirmed, in the future gene therapy will play a big role in the treatment.
Homenda
Wojciech
W
Z II Oddziału Chorób Wewnetrznych Hematologii i Endokrynologii Wojewódzkiego Szpitala Specjalistycznego w Słupsku. wojhom@sl.home.pl
Pejska
Michalina
M
Kochanowska-Demczyna
Aneta
A
D017209:Apoptosis / Q000187:drug effects; D016026:Bone Marrow Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000503:physiopathology* / Q000628:therapy*; D016896:Treatment Outcome